Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli

Ann Rheum Dis. 2022 Aug 11;81(9):e158. doi: 10.1136/annrheumdis-2020-218612.

Emanuel Della-Torre^{1

2}, Corrado Campochiaro^{3

2}, Giulio Cavalli^{3

2}, Giacomo De Luca^{3

2}, Fabio Ciceri^{2

4}, Alberto Zangrillo^{2

5}, Lorenzo Dagna^{3

2}

¹ Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), San Raffaele Scientific Institute, Milan, Italy dellatorre.emanuel@hsr.it.
² Vita-Salute San Raffaele University, San Raffaele Scientific Institute, Milan, Italy.
³ Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), San Raffaele Scientific Institute, Milan, Italy.
⁴ Hematology and Bone Marrow Transplant Unit, San Raffaele Scientific Institute, Milan, Italy.
⁵ Department of Anesthesia and Intensive Care, San Raffele Scientific Institute, Milan, Italy.

No abstract available

Keywords: anti-inflammatory agents; cytokines; inflammation; interleukin 1 receptor antagonist protein; non-steroidal; therapeutics.